HOME >> BIOLOGY >> NEWS
Gene chips help gauge chemotherapy's effectiveness in adult leukemia patients

BOSTON Taking a "snapshot" of gene activity can help doctors to determine which adult leukemia patients are likely to benefit from therapy and how long their remission is likely to last, researchers at Dana-Farber Cancer Institute and the University "La Sapienza" in Rome have found.

In a study to be published in the April 1 issue of Blood, researchers used "gene expression analysis" to measure the degree of activity of thousands of genes in 33 patients who had recently been diagnosed with adult T cell acute lymphocytic leukemia (T-ALL), a disease caused by the overproduction of immune cells known as T lymphocytes.

"The present study investigates, for the first time, the identification of gene expression profiles associated with both short-term and long-term outcome in adult patients with T-ALL," says Jerome Ritz, MD, of Dana-Farber, who served as senior author of the study with Robin Foa, MD, of the University "La Sapienza." "While approximately 70 percent of pediatric patients with T-ALL have excellent long-term response to intensive chemotherapy, adult patients have a much less favorable outcome. Previously, this poor prognosis of adult T-ALL patients had not been attributed to specific genetic events."

Sabina Chiaretti, MD, a research fellow at Dana-Farber, is the paper's first author.

Using microarray technology, investigators compared gene activity levels in patients who improved with chemotherapy to those who did not. The researchers identified a single gene, IL-8, that was unusually active or "highly expressed" in T-ALL cells from patients whose condition was resistant to chemotherapy.

They also found a group of 30 genes that were highly expressed in leukemic cells from patients who had complete remissions of the disease. By measuring the expression levels of three of those genes AHNAK, TTK, and CD2 researchers were able to correctly predict the duration of remission in 71 percent of the cases. Using the genes'
'"/>


19-Mar-2004


Page: 1 2

Related biology news :

1. Gene chips research in cotton could lead to superior variety
2. Purdue engineers develop quick, inexpensive method to prototype microchips
3. Salk news: Gene chips and crop yield
4. Purdue instrument to fashion custom-made proteomics chips
5. St. Jude researchers use DNA chips to determine how leukemia cells respond to different drugs
6. Scientists using gene chips identify a unique form of leukemia
7. Gene chips bring new order to lung cancer types, could yield sharper diagnoses, better drugs
8. Genomes on chips boon to cancer research
9. Gene chips accurately diagnose four complex childhood cancers
10. DNA gene chips and novel software used to describe kidney development
11. Tiny microchips have big promise in fighting serious diseases

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/5/2020)... ... , ... Regenative Labs has received approval from the Centers for Medicare & ... first Wharton’s jelly allografts to be assigned a Q code and be approved for ... Wharton’s jelly allograft product to be recognized as a 361 HCT/P by CMS regulated ...
(Date:7/18/2020)... ... July 16, 2020 , ... A study has been published ... Neoasis™ active noise control device to attenuate typical noises in a simulated neonatal ... the alarm sounds from patient monitors, ventilators and other bedside devices that would ...
(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com ... a biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European ... J Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... FARMS, Mich. (PRWEB) , ... August 12, 2020 ... ... Consulting Group, Inc. (EMMA International), a global leader in FDA compliance consulting ... of the nation’s fastest-growing private companies. The list represents a unique look at ...
(Date:8/3/2020)... (PRWEB) , ... August 03, 2020 , ... ... collection, today announced Jim Corrigan, President and CEO has been named one of ... broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on how ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... transmitter systems that can be configured to drive Klystrons, TWTs, IOTs, and magnetrons. ... drive one or two switches in a push-pull configuration; yielding fast fall time ...
Breaking Biology Technology:
Cached News: